POTP – Thanks for your reply. If only 0.002 of alpha is being allocated to this unscheduled interim look, as you stated, the chances would seem to be mighty slim.
>Best they can expect out of this is a trend towards improved PFS and overall survival in the drug arm vs placebo arm, and consequent continuation of the trial… I expect the trial will not be closed due to futility.<
Generally, the only information the trial sponsor obtains from such an interim data look in a blinded trial is that the trial is or is not continuing—the quantitative magnitude of any trend in the data is not reported.
If the above is true in this case, you are saying that POTP may be able to garner financing merely because the trial is not stopped for futility. I have to wonder what kinds of investors would consider this a sufficient inducement to invest. Regards, Dew
Market Data 
Markets 
AI
